LRMR Average Annual Return Since 2014
Growth of $10,000.00
Without Dividends Reinvested Into LRMR

Also see:
LRMR stock yearly return 2015
LRMR stock yearly return 2016
LRMR stock yearly return 2017
LRMR stock yearly return 2018
LRMR stock yearly return 2019
LRMR stock yearly return 2020
LRMR stock yearly return 2021
LRMR stock yearly return 2022
LRMR YTD return
Compare LRMR average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 06/20/2014
End date: 03/23/2023
Start price/share: $237.60
End price/share: $4.41
Dividends collected/share: $0.00
Total return: -98.14%
LRMR Average Annual Return: -36.56%
Starting investment: $10,000.00
Ending investment: $185.51
Years: 8.76

LRMR average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for patients suffering from rare diseases using its cell penetrating peptide technology platform. Co.'s lead product candidate, CTI-1601, is a biologic fusion protein that is administered subcutaneously, consists of a cell penetrating peptide (CPP) genetically fused to human frataxin (FXN), and includes a mitochondrial targeting sequence. Using its proprietary peptide delivery technology, CTI-1601 carries the molecule from the intravascular space across the cell membrane and into the mitochondria where the CPP and the mitochondrial targeting sequence are cleaved off to yield mature FXN. The LRMR average annual return since 2014 is shown above.

The Average Annual Return on the LRMR average annual return since 2014 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether LRMR average annual return since 2014 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the LRMR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree LRMR Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Larimar Therapeutics (LRMR) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

LTRN Average Annual Return
LUCD Average Annual Return
LUMO Average Annual Return
LUNG Average Annual Return
LXRX Average Annual Return
LYEL Average Annual Return
LYRA Average Annual Return
MACK Average Annual Return
MASI Average Annual Return
MBIO Average Annual Return
More Healthcare companies »


LRMR Average Annual Return Since 2014 | | Copyright © 2021 - 2023, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.